Full Circle Brilliance: Dr. Steven L Chang's Return to Stanford as the 27th Dorothy Fenmore Visiting Professor
In a notable homecoming, Dr. Steven L Chang, an esteemed urologic oncologist and Associate Professor of Surgery at Harvard Medical School, visited Stanford as the 27th Dorothy Fenmore Visiting Professor in Urology. This event marked Dr. Chang’s return to his alma mater, where he had previously completed his Urology residency training and Urologic Oncology fellowship at Stanford University Medical Center.
The Maxwell J. and Dorothy Fenmore Lectureship on Cancer Research, established in 1988 by the Fenmore family, annually invites eminent leaders in academic urology and cancer research to share their insights with the Stanford community. Dr. Chang, holding the position of Associate Professor of Surgery at Harvard Medical School (HMS), delivered two impactful presentations during his visit.
On Thursday, February 15, 2024, at a Special Grand Rounds Seminar, Dr. Chang delivered a presentation titled "Management of the Incidental Small Renal Mass: Lessons over the Past 20+ Years." The following day, Friday, February 16, 2024, marked the 27th Dorothy Fenmore Visiting Professorship Lecture, where Dr. Chang took center stage to discuss "The Evolving Role of Cytoreductive Nephrectomy." His comprehensive exploration of the subjects provided insights into the evolving landscape of urologic oncology. Attendees included Stanford Urology faculty, residents, fellows, and staff.
Dr. Chang's ties to Stanford run deep. After earning his medical degree from Columbia University, College of Physicians & Surgeons, he joined Stanford University Medical Center for his residency and fellowship training. Dr. Chang currently serves as the Associate Professor of Surgery at Harvard Medical School (HMS), and Division Chief of Urologic Oncology, the Department of Urology, Brigham and Women’s Hospital (BWH). In his role at BWH, Dr. Chang leads a dynamic team of nine urologic oncologists in collaboration with medical oncologists and radiation oncologists at the Lank Center for Genitourinary Oncology at DFCI.
As a familiar face in familiar halls, Dr. Chang's journey has come full circle, leaving an indelible mark on Stanford's rich history in urologic oncology.